non-small cell lung cancer
FDA Accepts BMS's NDA for Repotrectinib in ROS1-Positive NSCLC
The agency is reviewing data from the Phase II TRIDENT trial and expects to decide whether to approve the drug by November 27.
EMA's CHMP Recommends BMS's Opdivo, Chemo for Neoadjuvant PD-L1-Positive NSCLC
If approved, the drug combination will be the first immunotherapy-based treatment available in the neoadjuvant setting for NSCLC patients in Europe.
Panbela Therapeutics, Moffitt Cancer Center Testing Immunotherapy Enhancer in STK11-Mutant NSCLC
The partners will evaluate Panbela's eflornithine with Merck's Keytruda in a Phase I/II trial as proof of concept for modulating the immune system using polyamines and standard therapies.
Micronoma, NYU Partner to Develop Microbial Biomarkers of Lung Cancer
Micronoma aims to commercialize the biomarkers as a test based on its OncobiotaLUNG microbiome-based liquid biopsy platform.
AstraZeneca Sees New Lung Cancer Indication for Tagrisso, Chemo in FLAURA2 Data
Based on high-level results from the trial, the firm believes the combination could be a new first-line option for patients with advanced EGFR-mutated NSCLC.